CD30-positive lymphoproliferative disorders-An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre
- Author(s)
- Bhabha, FK; McCormack, C; Campbell, BA; Lade, S; Buelens, O; van der Weyden, C; Prince, HM;
- Details
- Publication Year 2023-05,Volume 64,Issue #2,Page 194-203
- Journal Title
- Australasian Journal of Dermatology
- Publication Type
- Review
- Abstract
- The CD30-postive lymphoproliferative disorders, including lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma, account for up to 30% of all cutaneous T-cell lymphomas (CTCLs) and are the second most common form of CTCLs after mycosis fungoides. Both conditions differ in their clinical presentations; however, they share the expression of the CD30 antigen as a common immunophenotypic hallmark. There is a wide spectrum of management options depending on factors such as extent of disease, staging and treatment tolerability. This Clinical Practice Statement is reflective of the current clinical practice in Australia.
- Publisher
- Wiley
- Keywords
- Humans; Australia; Ki-1 Antigen/metabolism; *Lymphomatoid Papulosis/diagnosis/therapy/pathology; *Lymphoproliferative Disorders/diagnosis/therapy; *Skin Neoplasms/diagnosis/therapy/pathology; CD30 lymphoproliferative disorders; cutaneous T cell lymphoma; lymphomatoid papulosis; primary cutaneous anaplastic large cell lymphoma
- Department(s)
- Surgical Oncology; Radiation Oncology; Pathology; Clinical Haematology
- PubMed ID
- 36892928
- Publisher's Version
- https://doi.org/10.1111/ajd.14016
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-08-08 01:28:49
Last Modified: 2023-08-08 01:31:07